IMPLANET: Nomination of a US Healthcare Reimbursement and Finance Expert to the Board of Directors

PARIS--()--Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces today the decision of the Board of Directors to nominate Mary E. Shaughnessy as a new Board Director.

Drawing on 20 years of experience working for Partners Healthcare System in Boston, Mary brings a wealth of specific expertise in the healthcare finance and reimbursement sector. In her capacity as the Senior Vice President of Finance, Partners Continuing Care (PCC), Mary has played an integral role in the strategic planning process, reviewed monthly financial results to maximize revenue, improved payment rates from commercial and government payers and implemented a payer / service line profitability analysis for respective hospitals within Partners.

Mary E. Shaughnessy says: “I am excited about the opportunity, impressed by the management team and I look forward to working with a solutions oriented company with novel technology that can make a real difference in patients’ lives. The technology that Implanet is developing will also provide physicians with important tools in a fast moving healthcare environment.”

Ludovic Lastennet, CEO, concludes, “We are proud to welcome Mary E. Shaughnessy as an independent Board Director. Her vast experience in hospital administration and reimbursement strategies will prove invaluable as Implanet expands the JAZZ technology platform in a reimbursement environment that compels medical device suppliers to provide demonstrable value added benefits as an essential complement to documented clinical efficacy.”

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

DISCLAIMER
This press release contains forward-looking statements related to Implanet and its activities. Implanet estimates that these forward-looking are based on reasonable assumptions. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in Implanet Reference Document registered with the French Autorité des marchés financiers (a copy of which is available on www.implanet-invest.com), and to the development of economic conditions, the financial markets and the markets in which Implanet operates. Forward-looking statements included in this press release are also subject to risks unknown for Implanet or not considered by Implanet as significant as of today. The Company's future performance, the Company’s financial position, results, cash-flows and developments in the sector may differ materially due to the realization of one of those risk factors.

Contacts

IMPLANET
Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen, Tel.: +1 917 385 21 60
implanet@alphabronze.net

Contacts

IMPLANET
Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen, Tel.: +1 917 385 21 60
implanet@alphabronze.net